"Ozempic Face" could arguably put more wind in the sails of RVNC and competitors.
https://www.forbes.com/sites/ariannajohnson/2023/02/01/ozempic-face-explained-why-it-happens-and-how-to-fix-it/?sh=65eeb8bd22c3

By the way, it was the last CFO who was apparently the architect of the financial engineering gimicks which have squandereed literally hundreds of millions of dollars on expensive stock buybacks. I'm glad she is gone.

Yes, the efgartigimod delay was noted here; not welcome news but was not greeted with panic either.
Other negative issues are related patent durability and, recently, some glimmers of competition with the rHuph20 enzyme.
Helen's leadership is looking shakier than ever but my feeling is that the BOD is composed of people she has helped select, so no ope of a leadership change, despite the crying need for it.
I do hope and expect that Helen will be grilled on the next CC. It should be interesting.
Feel free to drop in on West Pharma and make a pitch for the buyout. LOL!!

The deal offers no immediate prospects for future earnings for HALO but argenx has an active partnership with Halozyme that is on the cusp of being very significant for both companies. The hope is that, given this success, they will continue that relationship down the road.

Vin, sorry, I was addressing the guy who was criticising your post without giving his reasons for doing so. Apologise for the ambiguity.
Best,
-Fritz

Please explain your thinking.

Finally the GOP now has an alternative to Obamacare.

Needham's Serge Belanger reiterates buy rating and $40 PT

argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

https://ih.advfn.com/stock-market/NASDAQ/argenx-ARGX/stock-news/90773083/argenx-and-genmab-enter-partnership-to-advance-ant

Right, the option activity is nil but I'm keeping a half an eye on the bids. There is some interest, or at least it appeared that way, but no seller stepped up to the plate. We're never going to see anything like the highs of recent times unless there is a breathtaking deal, and that is looking very unlikely. I think mid-40s might be the best we can hope for at the moment, aside from the unknown unknowns. Helen has driven this car into a ditch. The BOD is probably in her pocket, so no relief coming either.

What else are you looking at in regard to other opportunities?

Rumsfeld the proto fascist, like his current full on fascist successors, was a bottomless pit of ignorance and lies.
That being said, given the imperfect state of our grasp of reality, what is your currrent take on HALO's prospects near and mid term?

Hmmm, if the universe of knowable things = infinity,
does that mean that within the observer there can be no increase of knowledge
and all learning must still = n+zero?

For a while today I noticed a decent bid on the June $45 calls, but nobody sold into it. Therein might be a clue as to the timing of an announcement. Just speculating here.

3rd CFO in (approximately) the last 7 years. The middle one was the authoress of the buyback and other financial engineering gimmicks.
Agreed about the dividend. They constantly speak of "returning value to the shareholders" and a look at the chart shows the full nature of their accomplishments.

Nope. They were sellers, not buyers. We shareholders give them lots of freebies, so they're not going to be buying with their own cash.

Berenberg Bank resumes coverage and institutes a $58 PT. I don't know this bank, but that call is an outlier nowadays.

I'm assuming this is Phesgo, FDA approved in 2020. When was the patent application filed?

TAK-881 is basically Hyqvia, but at double the immunoglobulin concentration, i.e., from 10% to 20%.

TAK-881 is mentioned in HALO's partner pipeline:
https://halozyme.com/drug-delivery-technologies/enhanze/

Wells Fargo maintains overweight but reduced PT from $55 to $48.

Thanks for the links. It is a human enzyme so it is a potential competitor to HALO's fundamental proposition. Do you have any thoughts on whether this product is going to be able to survive patent scrutiny?

Regarding other competitors using hyaluronidase, Enhanze definitely holds the competitive advantage, being a human derived and patent protected product, whereas the other enzymes have historically been derived from swine. So, if Merck, et. al, are using human derived hyaluronidase they may face patent challenges from Halozyme.

Just put up the link. It's an 8-K. A strange thing, given how tight lipped they've been on this topic over the years. My guess is that someone at HALO accidentally spilled the beans to an analyst or the like, and after that "oh shit!" moment and after consulting with the legal dept. they had to make it publicly known. Utter chaos.

https://ih.advfn.com/stock-market/NASDAQ/halozyme-therapeutics-HALO/stock-news/90521856/current-report-filing-8-k

Wells Fargo lowers PT to $55, maintains overweight.

I believe you are confusing the COM patent for Enhanze, which is unscathed, with the co-formulation patents of Enhanze added to another product, which is now in highly in doubt, at least in Europe.

SVB Leerink downgrades HALO and sets PT at $42.

Broadly speaking, the loss of co-formulation patent extension rights undercuts HALO's value to possible partners who saw that protection advantage as a motivation to pursue subcu products. Assuming this protection is no longer a workable model (this is not totally clear yet, so I'm speaking worst case scenario) any future partnerships will solely be based on consumer preference and convenience, a more slender reed to be sure.
This ruling may even affect the pending "three new deals" mentioned by Helen in her recent comments. If they are still able to get thiese deals over the goal line, then that'll be a good sign, but delays in this regard will be telling.

Yet another PR: The "unique" Janssen license does not extend the royalty step down in any event.

That's not what I said.

Thanks. Source? I don't see a company PR on my feed, but that is not unusual as it is sometimes late showing up.

SVB Leerink has coverage on HALO. Does anyone know if HALO has any assets lodged with SVB?

My impression is that everything Antares related is small ball, but it does drop some coins in the piggy bank. The injectors themselves are currently a potentially underappreciated asset that might be employed more widely and strategically, but that is to be seen down the road.

If you want me to delete something you have posted here just ask.

Welcome to the board. Feel free to share what you wish.
Good luck!
-Fritz

Any PT in the mid 60's is a long shot, but not impossible. It requires not only clearing away the pending patent issue, it also requires new deals that are significant, not just another humdrum treading of water.

MS lowers PT from $65 - $64, maintiains overweight rating.

Thanks for sharing. I agree that this bears close scrutiny.